NKGen Biotech (NYSE:NKGN) Trading 4.3% Higher – Here’s What Happened

NKGen Biotech, Inc. (NYSE:NKGN)’s stock price was up 4.3% during mid-day trading on Monday . The stock traded as high as $0.13 and last traded at $0.12. Approximately 41,781 shares were traded during mid-day trading, a decline of 98% from the average daily volume of 1,894,690 shares. The stock had previously closed at $0.12.

NKGen Biotech Price Performance

The firm has a market capitalization of $5.66 million, a P/E ratio of -0.02 and a beta of 0.83. The business has a 50 day moving average price of $0.29 and a 200 day moving average price of $0.39.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Magnetar Financial LLC acquired a new stake in NKGen Biotech in the 4th quarter worth $175,000. Kepos Capital LP bought a new stake in shares of NKGen Biotech in the fourth quarter valued at about $151,000. Sequoia Financial Advisors LLC grew its position in NKGen Biotech by 126.1% during the fourth quarter. Sequoia Financial Advisors LLC now owns 156,000 shares of the company’s stock worth $102,000 after buying an additional 87,000 shares in the last quarter. Geode Capital Management LLC raised its holdings in NKGen Biotech by 12.8% in the 4th quarter. Geode Capital Management LLC now owns 127,168 shares of the company’s stock valued at $83,000 after acquiring an additional 14,454 shares in the last quarter. Finally, Advisory Research Inc. bought a new stake in shares of NKGen Biotech in the 4th quarter worth approximately $28,000. 76.17% of the stock is currently owned by institutional investors and hedge funds.

About NKGen Biotech

NKGen Biotech, Inc operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials.